Technology
Health
Pharmaceutical

Novus Therapeutics

$1.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.21 (-10.10%) Today
+$0.03 (1.60%) After Hours

Why Robinhood?

You can buy or sell NVUS and other stocks, options, ETFs, and crypto commission-free!

About

Novus Therapeutics, Inc. Common Stock, also called Novus Therapeutics, is a pharmaceutical company, which engages in the acquisition, development, and commercialization of products for disorders of the ear, nose, and throat. Read More Its product pipelines include OPO201; OP0101; and OP0102. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.

Employees
10
Headquarters
Irvine, California
Founded
2004
Market Cap
19.60M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
60.67K
High Today
$2.05
Low Today
$1.83
Open Price
$2.05
Volume
58.61K
52 Week High
$8.61
52 Week Low
$1.52

Collections

Technology
Health
Pharmaceutical
Therapy
2014 IPO
US
North America

News

NasdaqMay 7

Tuesday 5/7 Insider Buying Report: NLY, NVUS

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money.

1,196
Yahoo FinanceMay 2

Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market

IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the closing of its previously announced registered direct offering of 3,449,112 shares of its common stock, at a purchase price per share of $3.095, priced at-the-market, to healthcare-focused institutional investors, led by OrbiMed, BVF Partners L.P., and Armistice Capital. Novus also issued unr...

203

Earnings

-$0.52
-$0.35
-$0.17
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.48 per share
Actual
-$0.52 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.